Orchestra BioMed Holdings, Inc.
As of Oct 22, 2026, Orchestra BioMed Holdings is in Stage 2, the uptrend phase, now in week 8 (since Aug 27, 2026). It closed at $5.47, 13.9% below its 52-week high and above its 200-day average, which is rising.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is OBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OBIO among Biotechnology107th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …107 | OBIO | Stage 2 · wk 8 | 82 | −7.8% |
Orchestra BioMed Holdings: quick answers
What stage is Orchestra BioMed Holdings in?
As of Oct 22, 2026, Orchestra BioMed Holdings (OBIO) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 27, 2026 and is in week 8. What the four stages mean
Is Orchestra BioMed Holdings in an uptrend?
Yes. Orchestra BioMed Holdings is in a Stage 2 uptrend. It trades 21.6% above its 200-day average, which is rising.
How far is Orchestra BioMed Holdings from its 52-week high?
Orchestra BioMed Holdings closed at $5.47 on Oct 22, 2026, 13.9% below its 52-week high of $6.35. Its 52-week low is $3.49.
How has Orchestra BioMed Holdings performed over the past year?
As of Oct 22, 2026, Orchestra BioMed Holdings is up 40.6% over the past year and up 26.9% so far in 2026.
Which sector and industry is Orchestra BioMed Holdings in?
Orchestra BioMed Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.